Korean biotech developing kinase-inhibitor cancer drugs, with a subsidiary that licensed a leukemia drug candidate to a global partner.
Korean biotech developing kinase-inhibitor cancer drugs, with a subsidiary that licensed a leukemia drug candidate to a global partner.
Has no marketed product of its own, so it relies on milestone payments from licensing partners and on share sales while candidates move through trials. Kinase inhibitors, the drug class it works in, block enzymes that tumours depend on.
Moat: narrow (IP / patents). Kinase-inhibitor drug-discovery platform validated by an out-licensed leukemia candidate.
Headquarters: Seongnam, South Korea · Founded: 1998 · Employees: 57
Size Oscotec (039200.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $923M, the 246th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩32,300 on 18 Nov 2026.
Performance Over six months the shares fell 32.3%, against -16.9% for the median peer and -37.2% for the South Korea market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue grew 510.3% over the last twelve months (peer median +2.4%); the operating margin is 58.8% (peer median 7.1%).
Valuation It trades at 50.2× forward earnings against a peer median of 22.2× (most expensive of 9).
Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -28 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 147.7 points above its cost of capital (5.6% WACC).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩142B | ₩99.8B | ₩34.0B | ₩4.95B | ₩5.06B |
| Revenue growth | — | +194% | +587% | -2% | — |
| Gross profit | ₩139B | ₩96.5B | ₩30.2B | ₩1.23B | ₩1.57B |
| EBITDA | ₩84.9B | ₩53.7B | -₩795M | -₩30.8B | -₩26.9B |
| Net income | ₩76.9B | ₩52.6B | ₩877M | -₩24.3B | -₩24.4B |
| Free cash flow | ₩86.5B | ₩7.52B | -₩26.7B | -₩22.6B | -₩27.7B |
| Capital expenditure | ₩1.48B | ₩780M | ₩692M | ₩581M | ₩1.25B |
| Total debt | ₩17.1B | ₩15.6B | ₩13.8B | ₩24.6B | ₩10.1B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Oscotec 039200.KS | $923M | -32% | +510% | 59% | 50.2× | -10.2% |
| Voronoi 310210.KS | $1.43B | -62% | -100% | -438,152% | n/a | n/a |
| HanmiPharm 128940.KS | $3.95B | -2% | +14% | 16% | 15.0× | 4.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 039200.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.9% | -9.1% | 7th lowest of 21 |
| 6-month return | -32.3% | -16.9% | 7th lowest of 20 |
| Distance from 52-week high | -51.1% | -46.6% | 7th lowest of 21 |
| Revenue growth (TTM) | +510.3% | +2.4% | highest of 18 |
| Operating margin | 58.8% | 7.1% | highest of 18 |
| Forward P/E | 50.2× | 22.2× | most expensive of 9 |
| Growth the price implies (Req g, 7 yrs) | -10.2% | 9.1% | least demanding of 12 |
| Growth delivered (Del g) | +18.1% | +4.9% | 2nd highest of 12 |
| Hurdle (Req g minus delivered) | -28.3 pp | +2.8 pp | least demanding of 12 |
| ROIC minus cost of capital | +147.7 pp | -2.0 pp | highest of 15 |
| EV / EBITDA | 12.5× | 11.1× | 3rd most expensive of 6 |
| Net debt / EBITDA | -2.0× | 2.1× | least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Oscotec 039200.KS | South Korea | $923M | -32% | +510% | 59% | 50.2× | -10.2% | +18.1% |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $922M | -14% | +2% | 24% | 22.9× | 9.1% | +13.4% |
| Lotus Pharmaceutical 1795.TW | Taiwan | $921M | -37% | +67% | 21% | 9.8× | -3.7% | +13.8% |
| MoonLake Immunotherapeutics MLTX | United States | $918M | -37% | n/a | n/a | n/a | n/a | n/a |
| Bio-Thera Solutions 688177.SS | China | $929M | -23% | +24% | -44% | n/a | n/a | n/a |
| Immatics IMTX | United States | $913M | -46% | -44% | -589% | n/a | n/a | n/a |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | n/a | n/a | n/a |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $936M | -10% | -43% | -42% | n/a | 10.3% | -13.7% |
| KPC Pharmaceuticals 600422.SS | China | $940M | -6% | -41% | -10% | n/a | n/a | n/a |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $941M | -9% | -16% | 13% | n/a | 7.7% | -6.9% |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $904M | -28% | +14% | 7% | n/a | 19.4% | -6.0% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $945M | -48% | +19% | 9% | 42.3× | 11.6% | +4.9% |
| Strides Pharma Science STAR.NS | India | $946M | -17% | +11% | 14% | 15.9× | 17.6% | +7.8% |
| SSY 2005.HK | Hong Kong | $948M | +8% | -4% | 12% | 12.5× | 2.3% | -0.5% |
| Aktis Oncology AKTS | United States | $895M | -15% | +337% | -837% | n/a | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $895M | -14% | -6% | 3% | n/a | -7.6% | -0.7% |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 21.4× | n/a | n/a |
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| Latigo Biotherapeutics LTGO | United States | $882M | n/a | n/a | n/a | n/a | n/a | n/a |
| Nxera Pharma 4565.T | Japan | $974M | +46% | +24% | 14% | 25.8× | 17.7% | +27.3% |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 24.5× | 5.6% | +9.3% |